The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
Authors:
- Alessandro MatteAMAlessandro Matte
- Enrica FedertiEFEnrica Federti
- Charles KungCKCharles Kung
- Penelope A. KosinskiPKPenelope A. Kosinski
- Rohini NarayanaswamyRNRohini Narayanaswamy
- Roberta RussoRoberta Russo
- Giorgia FedericoGFGiorgia Federico
- Francesca CarlomagnoFCFrancesca Carlomagno
- Maria Andrea DesbatsMDMaria Andrea Desbats
- Leonardo SalviatiLSLeonardo Salviati
- Christophe LeboeufCLChristophe Leboeuf
- Maria Teresa ValentiMaria Teresa Valenti
- 17 May 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (10)
Abstract
Anemia in β-thalassemia is related to ineffective erythropoiesis and reduced red cell survival. Excess free heme and accumulation of unpaired α-globin chains impose substantial oxidative stress on β-thalassemic erythroblasts and erythrocytes, impacting cell metabolism. We hypothesized that increased pyruvate kinase activity induced by mitapivat (AG-348) in the Hbbth3/+ mouse model for β-thalassemia would reduce chronic hemolysis and ineffective erythropoiesis through stimulation of red cell glycolytic metabolism. Oral mitapivat administration ameliorated ineffective erythropoiesis and anemia in Hbbth3/+ mice. Increased ATP, reduced reactive oxygen species production, and reduced markers of mitochondrial dysfunction associated with improved mitochondrial clearance suggested enhanced metabolism following mitapivat administration in β-thalassemia. The amelioration of responsiveness to erythropoietin resulted in reduced soluble erythroferrone, increased liver Hamp expression, and diminished liver iron overload. Mitapivat reduced duodenal Dmt1 expression potentially by activating the pyruvate kinase M2-HIF2α axis, representing a mechanism additional to Hamp in controlling iron absorption and preventing β-thalassemia–related liver iron overload. In ex vivo studies on erythroid precursors from patients with β-thalassemia, mitapivat enhanced erythropoiesis, promoted erythroid maturation, and decreased apoptosis. Overall, pyruvate kinase activation as a treatment modality for β-thalassemia in preclinical model systems had multiple beneficial effects in the erythropoietic compartment and beyond, providing a strong scientific basis for further clinical trials.Keywords
Funding Information
- Agios Pharmaceuticals, Inc. (research collaborative grant)
This publication has 73 references indexed in Scilit:
- Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic miceHaematologica, 2013
- Analysis of GSH and GSSG after derivatization with N-ethylmaleimideNature Protocols, 2013
- Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2Molecular Cancer, 2013
- Oxidative Stress and-Thalassemic Erythroid Cells behind the Molecular DefectOxidative Medicine and Cellular Longevity, 2013
- YME1L controls the accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae morphogenesis, and cell proliferationMolecular Biology of the Cell, 2012
- Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant ResponsesScience, 2011
- Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in -thalassemic erythropoiesisHaematologica, 2011
- Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1Cell, 2011
- Peroxiredoxin-2 expression is increased in β-thalassemic mouse red cells but is displaced from the membrane as a marker of oxidative stressFree Radical Biology and Medicine, 2010
- Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportinBlood, 2007